Articles related to Hematology/Oncology

In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL). Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from MSKCC.

The possible answer was presented during the 2020 ASH Annual Meeting, bringing into question whether current recommendations for prophylactic intravenous high-dose methotrexate — the most widely adopted method for CNS relapse prevention — are appropriate for all patients at high risk of a CNS relapse.

Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing  the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.

Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Discover what the American Society of Hematology (ASH) recommends for your older adult AML patients.

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.